Phillips Wealth Planners LLC Sells 511 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Phillips Wealth Planners LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,171 shares of the biopharmaceutical company’s stock after selling 511 shares during the period. Phillips Wealth Planners LLC’s holdings in Gilead Sciences were worth $375,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. FMR LLC grew its position in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after buying an additional 11,665,593 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after acquiring an additional 1,793,145 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after acquiring an additional 1,622,806 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $102,298,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. Bank of America reaffirmed a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research note on Tuesday, December 10th. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Piper Sandler lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price target for the company. Finally, Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is owned by insiders.

Gilead Sciences Price Performance

Shares of GILD opened at $93.04 on Thursday. The firm has a market capitalization of $115.95 billion, a PE ratio of 1,033.78, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company’s fifty day moving average price is $91.62 and its 200-day moving average price is $84.57.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the company earned $2.29 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.